Fig. 2: Vaccine immunogenicity.
a Median and IQR magnitude of total HTI-specific T-cell response (sum of SFCs per 106 PBMCs for HTI pools P1–P10) over time in 33 CCMM + VES (shown in red) and 17 placebo (shown in blue) recipients from baseline to week 48. Statistics are derived from data from 24–30 (out of 33) CCMM + VES recipients and 13–16 (out of 17) placebo recipients at each timepoint, depending on sample availability and valid results after assay QC. Arrows indicate vaccination or VES/placebo administration dates. BL baseline, C ChAdOx1.HTI, M MVA.HTI, P placebo. b Individual magnitudes of HTI-specific response (sum of SFCs per 106 PBMCs for HTI pools P1–P10) in CCMM + VES (shown in red) and placebo (shown in blue) recipients, at study entry (BL), the timepoint between study entry and week 48 with the strongest observed total HTI-specific T-cell responses (peak) and at week 48 (ATI start). P value tested using a two-sided van Elteren test (P value <0.0001; unadjusted for multiple comparisons, with 5% error rate), with a stratification factor for the actual potential for superior viral control (yes/no). c Median contribution of HTI-specific T cells to total virus-specific responses, according to specificity. HTI-specific responses are shown in red for CCMM + VES and in blue for placebo recipients; non-HTI HIV-1-specific responses are shown in gray. d Median and IQR breadth of total HTI-specific T-cell response (number of reactive HTI pools P1–P10) over time in 33 CCMM + VES (red) and in 17 placebo (blue) recipients from baseline to week 48. Statistics are derived from data of 24–30 (out of 33) CCMM + VES recipients and 13–16 (out of 17) placebo recipients at each timepoint, depending on sample availability and valid results after assay QC. Arrows indicate vaccination or VES/placebo administration dates. e Distribution of HTI-specific responses within the different HIV-1 subproteins at study entry (BL) and accumulated up to the start of ATI for each placebo (P01–P17) and CCMM + VES (V01–V30) recipient.
